> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Guidance on Generic Drug Controlled Correspondence
- URL: https://www.fdaweb.com/guidance-on-generic-drug-controlled-correspondence/
- Published: 2024-03-18T12:00:00.000Z
- Updated: 2026-09-14T14:25:40.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5156577

Federal Register notice: FDA is making available a final guidance entitled “Controlled Correspondence Related to Generic Drug Development .” The document provides information on how generic drug manufacturers submit controlled correspondence requesting information related to their product development. It also describes the agency’s process for providing responses related to the requests. The guidance updates program enhancements that FDA and industry agreed to under the recent reauthorization of the Generic Drug User Fee Amendments. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2024-03-18/pdf/2024-05687.pdf?ref=fdaweb.com).